Position in ANL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$22,232,098
New position
Shares Held
3,212,731
first reported quarter
Ownership
4.99%
of shares outstanding
% of Portfolio
0.83%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Venrock Adviser, LLC holds $2,679,121,844 across 33 Biotechnology names. ANL ranks #24 (0.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | APGE |
Apogee Therapeutics, Inc.
|
8,493,321 | $714,882,828 | |
| 2 | ERAS |
Erasca, Inc.
|
16,382,812 | $265,073,898 | |
| 3 | ORKA |
Oruka Therapeutics, Inc.
|
4,148,428 | $203,480,393 | |
| 4 | SYRE |
Spyre Therapeutics, Inc.
|
3,685,448 | $185,893,997 | |
| 5 | KALV |
KalVista Pharmaceuticals, Inc.
|
6,474,485 | $130,331,383 | |
| 6 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
1,180,000 | $99,025,600 | |
| 7 | DMRA |
Damora Therapeutics, Inc.
|
3,603,595 | $93,333,110 | |
| 8 | OCUL |
Ocular Therapeutix, Inc
|
10,346,926 | $87,638,463 |
All Filings in ANL
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $22,232,098 | 3,212,731 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||